JAZZ is setting up nicely and getting ready to go higherNASDAQ:JAZZ price action is bullish. Long the break out to target levels shown on the chart, stop daily close below 117$.
PS. My view only not financial advice!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.924 CHF
508.70 M CHF
3.70 B CHF
58.84 M
About Jazz Pharmaceuticals plc
Sector
Industry
CEO
Bruce C. Cozadd
Website
Headquarters
Dublin
Founded
2005
ISIN
IE00B4Q5ZN47
FIGI
BBG00LVDMT84
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
JAZZ downtrend intactWe can observe how the price continues to decline within the descending channel. Current pullback might present a solid RR selling opportunity.
Jazz Pharmaceuticals: High Life 🍁It must be 420 somewhere, since the Jazz Pharmaceuticals stock is paving its way higher and higher to ultimately reach the orange target zone. Once the blue wave (b) is completed, the stock should drop all the way below the $125.36 support line and continue the correction until the end of the green
JAZZ PHARMACEUTICALS Estimates DailyHey my friends, JAZZ PHARMACEUTICALS is in a bullish movement with a rising leg doji and low sell volume traded. In the TIMEFRAME M1 we notice a large hammer candle with a low return on purchase volume. She goes on the VWAP to test it as well as the bollinger's bollinger and ends up on the top of th
Cup and HandleFell from a rising wedge and off JAZZ went.
This one looked bearish for a while but is looking much better.
Cup low is 86.88 cup high is 154.24 Breakout is 154.34 ( a bit over cup high. Cup depth is 67.36
Mid cup is 129.56. Handle low is 139.6 Support is found here and last pivot low.
Tar
Cup and HandleJAZZ fell from a rising wedge that was narrowing but has perhaps fell as far as it will fall..
RW (rising wedges that narrow at apex) are almost always bearish ..it is often a long term pattern and not valid unless bottom trendline is broken..
OBV and NV are both high..short percent a bit higher t
Cup and HandleThere is also a Narrowing Rising Wedge in this chart
A rising wedge can be a very long term pattern that is caused by too much buying without healthy pull backs. "Irrational Exuberance"
In the end, there is a shortage of buyers and if the pattern breaks the bottom trendline, the pattern is valid.
Jazz Pharmaceuticals Announces Positive Top-line Results from PhJAZZ: Jazz Pharmaceuticals plc
2020-10-08 07:30:00
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia
JAZZ/USD Long$JAZZ looks to be in bullish continuation here:
On the 1D chart it looks like it wants to visit
$143/144
(potentially after a retest of the diagonal it
broke out from around $125)
Reasons:
-It had a strong breakout from a bullish pennant,
the target for this breakout would be the height
of the
$JAZZ Upside Targets Insider buying details
Mulligan Seamus Director May 27 Buy 111.26 35,000 3,894,058 1,152,788 May 27 06:36 PM
Mulligan Seamus Director May 26 Buy 110.65 15,000 1,659,747 1,117,788 May 27 06:36 PM
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
JAZZ5172103
Jazz Securities Designated Activity Company 4.375% 15-JAN-2029Yield to maturity
5.99%
Maturity date
Jan 15, 2029
JAZZ5206504
Jazz Investments I Ltd. 2.0% 15-JUN-2026Yield to maturity
1.88%
Maturity date
Jun 15, 2026
See all J7Z bonds
Related stocks
Frequently Asked Questions
The current price of J7Z is 83.098 CHF — it has decreased by −32.51% in the past 24 hours. Watch JAZZ PHARMA PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange JAZZ PHARMA PLC stocks are traded under the ticker J7Z.
J7Z stock has fallen by −32.37% compared to the previous week, the month change is a −32.37% fall, over the last year JAZZ PHARMA PLC has showed a −20.84% decrease.
We've gathered analysts' opinions on JAZZ PHARMA PLC future price: according to them, J7Z price has a max estimate of 189.99 CHF and a min estimate of 103.26 CHF. Watch J7Z chart and read a more detailed JAZZ PHARMA PLC stock forecast: see what analysts think of JAZZ PHARMA PLC and suggest that you do with its stocks.
J7Z stock is 48.18% volatile and has beta coefficient of 0.79. Track JAZZ PHARMA PLC stock price on the chart and check out the list of the most volatile stocks — is JAZZ PHARMA PLC there?
Today JAZZ PHARMA PLC has the market capitalization of 5.03 B, it has increased by 10.96% over the last week.
Yes, you can track JAZZ PHARMA PLC financials in yearly and quarterly reports right on TradingView.
JAZZ PHARMA PLC is going to release the next earnings report on Jul 30, 2025. Keep track of upcoming events with our Earnings Calendar.
J7Z earnings for the last quarter are 1.49 CHF per share, whereas the estimation was 4.12 CHF resulting in a −63.93% surprise. The estimated earnings for the next quarter are −4.33 CHF per share. See more details about JAZZ PHARMA PLC earnings.
JAZZ PHARMA PLC revenue for the last quarter amounts to 794.81 M CHF, despite the estimated figure of 870.88 M CHF. In the next quarter, revenue is expected to reach 880.28 M CHF.
J7Z net income for the last quarter is −81.92 M CHF, while the quarter before that showed 173.57 M CHF of net income which accounts for −147.20% change. Track more JAZZ PHARMA PLC financial stats to get the full picture.
No, J7Z doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 10, 2025, the company has 2.8 K employees. See our rating of the largest employees — is JAZZ PHARMA PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JAZZ PHARMA PLC EBITDA is 1.11 B CHF, and current EBITDA margin is 34.08%. See more stats in JAZZ PHARMA PLC financial statements.
Like other stocks, J7Z shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JAZZ PHARMA PLC stock right from TradingView charts — choose your broker and connect to your account.